CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 6852 result(s)

Insulin detemir (Levemir)

Last Updated: March 10, 2009
Result type: Reports
Product Line: Common Drug Review
Generic Name: Insulin detemir
Indications: Diabetes mellitus

  • Brand Name: Levemir
  • Manufacturer: Novo Nordisk Canada Inc.
  • Project Number: S0160
  • Project Status: Complete
  • Submission Type: Resubmission 2

Rasagiline mesylate (Azilect)

Last Updated: March 10, 2009
Result type: Reports
Product Line: Common Drug Review
Generic Name: Rasagiline mesylate
Indications: Parkinson’s disease

  • Brand Name: Azilect
  • Manufacturer: Teva Pharmaceuticals Industries Ltd.
  • Project Number: S0161
  • Project Status: Complete
  • Submission Type: Request For Advice

Insulin detemir (Levemir)

Last Updated: March 10, 2009
Result type: Reports
Product Line: Common Drug Review
Generic Name: Insulin detemir
Indications: Diabetes mellitus Type1, Pediatrics

  • Brand Name: Levemir
  • Manufacturer: Novo Nordisk Canada Inc.
  • Project Number: S0172
  • Project Status: Complete
  • Submission Type: New Indication

Desvenlafaxine succinate (Pristiq)

Last Updated: March 5, 2009
Result type: Reports
Product Line: Common Drug Review
Generic Name: Desvenlafaxine succinate
Indications: Depressive, Major Disorder (MDD)

  • Brand Name: Pristiq
  • Manufacturer: Wyeth Canada
  • Project Number: S0159
  • Project Status: Complete
  • Submission Type: New